Intra-Aortic Balloon Pump Insertion in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS (Primary Indications):

• Cardiogenic shock secondary to acute myocardial infarction (AMI) with or without revascularization (PCI/CABG)

• Refractory unstable angina unresponsive to maximal medical therapy (nitrates, beta-blockers, antiplatelet agents, heparin)

• Acute decompensated heart failure with low cardiac output syndrome (cardiac index < 2.2 L/min/m²)

• High-risk percutaneous coronary intervention (PCI) — unprotected left main disease, severely reduced ejection fraction (EF < 35%), or last remaining conduit

• Pre-operative stabilization for high-risk CABG or complex valve surgery (EuroSCORE II > 5%)

• Mechanical complications of AMI: acute severe mitral regurgitation (papillary muscle rupture) or post-infarction ventricular septal defect

• Bridge to VAD implantation or orthotopic cardiac transplantation

• Refractory ventricular arrhythmias with hemodynamic compromise

• REQUIRED DIAGNOSTIC WORKUP PRIOR TO IABP:

• 12-lead ECG and continuous cardiac monitoring (for counterpulsation trigger signal quality)

• Transthoracic Echocardiography (TTE) or Transesophageal Echocardiography (TEE): to assess LV ejection fraction, wall motion abnormalities, valvular pathology, and aortic root diameter

• Coronary Angiography (CAG) / CT Coronary Angiography (CTCA): to define coronary anatomy and revascularization targets

• Chest X-ray and CT Aortography: to assess thoracic aortic anatomy, calcification, and caliber prior to catheter insertion

• Complete Blood Count (CBC), Coagulation Profile (PT/INR, aPTT), Renal Function Tests (creatinine, eGFR): mandatory to assess bleeding risk and contrast nephropathy risk

• Arterial Blood Gas (ABG) and Lactate: to quantify severity of hemodynamic compromise

• Bilateral lower limb Doppler Ultrasound: to confirm adequate femoral arterial access and exclude peripheral arterial occlusive disease

• BNP or NT-proBNP: as a biomarker of heart failure severity and prognostication

• ABSOLUTE CONTRAINDICATIONS:

• Moderate-to-severe aortic regurgitation (IABP diastolic inflation worsens AR and increases regurgitant volume)

• Aortic dissection (any type) or known aortic aneurysm (significant risk of catastrophic aortic rupture)

• Severe bilateral peripheral arterial occlusive disease precluding safe femoral artery access

• Uncontrolled sepsis with aortic involvement

• RELATIVE CONTRAINDICATIONS:

• Severe unilateral peripheral arterial disease (alternative access sites — axillary/subclavian artery approach may be considered)

• Aorto-iliac occlusive disease or prior aortic surgery

• Severe coagulopathy or thrombocytopenia (platelet count < 50,000/µL) not amenable to correction

• Tachyarrhythmias (atrial fibrillation with rapid ventricular response, frequent PVCs) that impair reliable counterpulsation trigger — requires rate control or alternative trigger modes (pressure trigger)

IABP INSERTION TECHNIQUES:

1. Standard Percutaneous Femoral Approach (Most Common):

The femoral artery is accessed under sterile conditions using the modified Seldinger technique, typically via the common femoral artery below the inguinal ligament. A 7–8 Fr introducer sheath is placed, and the pre-wrapped balloon catheter (sized to patient height: 25 mL for patients < 152 cm, 34 mL for 152–162 cm, 40 mL for 162–182 cm, 50 mL for > 182 cm) is advanced over a 0.025–0.030-inch guidewire under fluoroscopic guidance. Final balloon position is confirmed with the radiopaque tip 2–3 cm distal to the origin of the left subclavian artery (at the level of the carina on chest X-ray, approximately at the T4–T5 level). The procedure takes 15–30 minutes in experienced hands. Unsheathed (sheathless) balloon catheters are preferred in patients with marginal peripheral vasculature to minimize limb ischemia risk.

2. Axillary / Subclavian Artery Approach (Ambulatory IABP):

In patients with severe peripheral arterial disease, bilateral femoral grafts, or in whom ambulation is required (bridge to transplantation scenarios), the left axillary or subclavian artery can be used for IABP insertion. A Dacron side-graft is sewn end-to-side to the axillary artery, through which the balloon catheter is passed. This approach allows limited patient mobility and is used in prolonged support scenarios (days to weeks).

3. Direct Aortic / Transapical Approach (Rare, Surgical):

Used intraoperatively during cardiac surgery when femoral and axillary routes are unavailable. The balloon is inserted directly into the ascending or descending aorta via surgical cutdown. This approach is performed by cardiac surgeons in the operating theater.

COUNTERPULSATION MODES AND CONSOLE TECHNOLOGIES:

• Trigger Modes: ECG-triggered (standard; R-wave onset triggers deflation), Arterial pressure-triggered (for paced rhythms or poor ECG signal), Pacemaker-triggered, and Internal (asynchronous) trigger for cardiac arrest scenarios.

• Timing Modes: Semi-automatic and Automatic (real-time microprocessor-adjusted inflation/deflation based on hemodynamic feedback — available on Getinge Cardiosave and Maquet CS300 platforms).

• Inflation Ratios: 1:1 (every heartbeat — maximum support), 1:2 or 1:3 (weaning modes — progressively reducing support as native cardiac function recovers).

• Fiber-Optic Pressure Monitoring: Eliminates hydrostatic damping artifacts and provides millisecond-accurate pressure waveform analysis for optimal inflation/deflation timing.

ADVANCED AND COMPLEMENTARY MECHANICAL CIRCULATORY SUPPORT:

• Impella (Axial Flow Catheter-Based VAD): For patients failing IABP support, escalation to Impella CP (3.5 L/min) or Impella 5.5 (5.5 L/min) provides superior hemodynamic support. The IABP-SHOCK II trial demonstrated that IABP alone did not reduce 30-day mortality in AMI-cardiogenic shock, prompting algorithm-based escalation to Impella in non-responders.

• VA-ECMO (Venoarterial Extracorporeal Membrane Oxygenation): Used for biventricular failure or refractory cardiogenic shock; can be combined with IABP (the 'ECpella' configuration) to unload the LV and prevent pulmonary edema.

• IABP as Bridge to Definitive Therapy: Serves as a hemodynamic bridge to PCI, CABG, VAD implantation, or cardiac transplantation in appropriately selected patients.

WEANING PROTOCOL:

Weaning is initiated when hemodynamic stability is achieved — defined as MAP > 70 mmHg on low-dose vasopressors (norepinephrine < 0.1 µg/kg/min), cardiac index > 2.2 L/min/m², and improving lactate clearance. The IABP ratio is progressively reduced from 1:1 to 1:2 to 1:3 over 4–24 hours, with hemodynamic assessment at each step. Upon successful weaning, the balloon is deflated, the catheter withdrawn, and manual compression or a vascular closure device (Perclose ProGlide, AngioSeal) applied to achieve femoral arterial hemostasis.

PHASE 1 — PRE-PROCEDURE ASSESSMENT AND STABILIZATION (Day 0–1):

• Emergency or elective admission to the Cardiac Care Unit (CCU) or Cardiac Catheterization Laboratory.

• Rapid hemodynamic assessment: vital signs, invasive arterial blood pressure monitoring, Swan-Ganz catheter placement (if indicated) to measure pulmonary capillary wedge pressure, cardiac output, and systemic vascular resistance.

• Urgent echocardiography (TTE/TEE) to define LV function, identify mechanical complications, and assess aortic valve competence.

• Coronary angiography performed simultaneously in AMI-cardiogenic shock patients to identify culprit vessel for revascularization.

• Blood work: CBC, coagulation profile, metabolic panel, troponin, BNP, lactate, ABG.

• Bilateral lower limb pulse assessment; Doppler ultrasound of femoral arteries if peripheral vascular disease is suspected.

• Informed consent obtained; patient and family counseled on procedure, risks, expected duration of support, and potential escalation therapies.

• Anticoagulation initiated: unfractionated heparin infusion (target aPTT 50–70 seconds) to prevent thrombus formation on the balloon.

PHASE 2 — IABP INSERTION PROCEDURE (Day 1; Duration: 15–45 minutes):

• Patient positioned supine on the catheterization table or operating table under continuous ECG and SpO₂ monitoring.

• Femoral groin prepared and draped in sterile fashion; local anesthesia (1% lidocaine) infiltrated over the common femoral artery.

• Percutaneous femoral arterial access achieved via modified Seldinger technique; 7–8 Fr introducer sheath inserted.

• Appropriately sized balloon catheter (size selected based on patient height) advanced over guidewire under live fluoroscopic guidance.

• Balloon position confirmed radiographically (tip 2–3 cm distal to left subclavian artery origin).

• Balloon connected to IABP console; helium gas connected; counterpulsation initiated at 1:1 ratio.

• ECG trigger confirmed; inflation/deflation timing optimized to arterial pressure waveform (classical 'diastolic augmentation' and 'assisted systolic pressure' waveform targets achieved).

• Sheath secured; dressing applied; distal limb pulses and capillary refill confirmed immediately post-insertion.

PHASE 3 — ICU MANAGEMENT AND HEMODYNAMIC SUPPORT (Day 1–5):

• Continuous monitoring in Cardiac ICU (CICU): ECG, invasive arterial line, central venous pressure, urinary output (target > 0.5 mL/kg/hr as a surrogate of cardiac output adequacy).

• Vasopressor management: Norepinephrine (first-line vasopressor), Dobutamine (inotrope for low cardiac output), Vasopressin (adjunct for vasoplegia) — doses titrated to MAP target ≥ 65–70 mmHg.

• Daily chest X-ray to confirm balloon position (migration is a recognized complication).

• Daily CBC and coagulation monitoring; heparin dose adjusted to maintain therapeutic anticoagulation.

• Hourly distal pulse checks (dorsalis pedis, posterior tibial) to detect limb ischemia.

• Concurrent treatment of underlying cause: PCI or CABG performed during IABP support in AMI-cardiogenic shock patients; medical optimization of heart failure.

• Renal protection: IV hydration, avoidance of nephrotoxic agents, monitoring for contrast-induced nephropathy.

PHASE 4 — WEANING AND IABP REMOVAL (Day 3–7, condition-dependent):

• Weaning criteria met: hemodynamic stability on low/no vasopressors, cardiac index > 2.2 L/min/m², improving clinical status.

• Sequential ratio reduction: 1:1 → 1:2 (4–12 hours) → 1:3 (4–12 hours) with hemodynamic reassessment at each step.

• If hemodynamic deterioration occurs during weaning, ratio is increased back to 1:1; escalation to Impella or VA-ECMO considered.

• Upon successful weaning: heparin held for 4 hours; balloon deflated; catheter and sheath removed; manual compression for 30–45 minutes or vascular closure device deployed.

• Post-removal observation for 6–8 hours: groin hematoma, retroperitoneal bleeding, distal limb ischemia.

PHASE 5 — POST-ICU CARE AND CARDIAC REHABILITATION (Day 5–10):

• Transfer to step-down cardiac unit; transition from IV to oral medications.

• Oral medications initiated: Dual antiplatelet therapy (aspirin + clopidogrel/ticagrelor for post-PCI patients), ACE inhibitor or ARB, beta-blocker, aldosterone antagonist, SGLT2 inhibitor (empagliflozin/dapagliflozin) for HFrEF, statin.

• Graded mobilization: sitting at bedside (Day 5–6), standing and short walks with physiotherapy supervision (Day 7–8), progressive ambulation (Day 9–10).

• Echocardiography repeated prior to discharge to reassess LV function recovery.

• Cardiac rehabilitation program enrollment discussed; outpatient follow-up scheduled.

• Patient education: medication adherence, warning signs of deterioration, dietary sodium restriction, activity guidelines.

PHASE 6 — PRE-DISCHARGE AND FIT-TO-FLY ASSESSMENT (Week 2–4):

• International patients undergo a formal fit-to-fly assessment by the treating cardiologist prior to authorizing air travel.

• Criteria for clearance: hemodynamically stable off all mechanical support and vasopressors for ≥ 7–14 days, ambulating independently, no active chest pain or dyspnea at rest, oxygen saturation ≥ 95% on room air, no uncontrolled arrhythmia, stable renal and hepatic function, wound/access site fully healed.

• For patients with EF < 30% or persistent heart failure symptoms, medical escort or aeromedical repatriation may be arranged by GAF Healthcare.

• Comprehensive discharge summary, imaging, procedural report, and medication list provided in English (and translated as required) for the receiving physician at the patient's home country.